NOVALIQ Strengthens Executive Management Team with the Appointment of Gabriela Burian, MD, MPH, as Chief Medical Officer
27.6.2017 19:00 | Business Wire
NOVALIQ GmbH, a specialty pharmaceutical company with a disruptive drug delivery platform that transforms poorly soluble drugs into effective therapeutics for ophthalmology, today announced the appointment of Gabriela Burian, MD, MPH, as NOVALIQ’s Chief Medical Officer (CMO).
Dr. Burian brings over 25 years of international clinical experience to the company. She is responsible for leading NOVALIQ’s global clinical development and regulatory efforts, as well as expanding the company’s proprietary ocular therapeutics pipeline. Dr. Burian has deep clinical knowledge and proven leadership in the areas of ophthalmic biomedical research and clinical translation, with specialized expertise in retina diseases. Previously, Dr. Burian held various leadership positions, including Global Program Medical Director at Novartis Pharma and Ophthalmology Early Program Leader at F. Hoffmann-La Roche. She founded and directs GB Biomed Advisors GmbH and serves as CMO for Iconic Therapeutics, Inc. She is a faculty member of the European School for Advanced Studies in Ophthalmology.
“NOVALIQ has a very exciting and robust dry eye therapy pipeline and has the potential to address significant clinical needs in retina and glaucoma as well,” said Dr. Burian. “With multiple pre-clinical and clinical stage programs in development, the company is strongly positioned to be a global leader in dry eye disease. My top priorities are to advance these programs toward regulatory submissions and to identify, develop and manage new drug development opportunities in glaucoma and retina diseases by harnessing the power of NOVALIQ’s proprietary EyeSol® technology, which enhances the topical bioavailability, stability and safety of traditionally insoluble or unstable drugs.”
Sonja Krösser, PhD, vice president of preclinical and clinical development will continue to lead NOVALIQ’s dry eye developments and remains responsible for the preclinical and clinical team. Dr. Krösser is a translational science and clinical development expert with more than 15 years in the biopharmaceutic industry and in-depth experience in dry eye disease. She was and will be instrumental in the advancement of NOVALIQ’s rich and differentiated dry eye product pipeline, which includes the CE-approved NovaTears®; NovaTears® Omega-3 a new preservative-free, multi-dose eye drop formulation expecting CE mark in 2017; CyclASol®, currently in Phase 2 clinical trials in the U.S.; and, the recently announced, first-in-class ocular pain and anti-inflammatory cannabinoid DED drug development program.
Dr. Burian will join NOVALIQ’s executive management team, reporting to the company’s managing director and CEO Christian Roesky, PhD. “I’m delighted to welcome Gabriela to NOVALIQ ,” said Dr. Roesky. “With Gabriela’s extensive experience leading medical and clinical development teams combined with Sonja’s demonstrated track record of advancing our dry eye pipeline, we are strengthening our mission to transform active pharmaceutical ingredients (APIs) into highly effective ocular therapeutics for both the front and the back of the eye.”
About NOVALIQ– NOVALIQ GmbH, founded in 2007, is a Heidelberg based specialty pharmaceutical company focused on ophthalmology. Its mission is to transform poorly soluble drugs into effective ocular therapeutics for both the front and the back of the eye. NOVALIQ’s proprietary EyeSol® technology enhances the topical bio-availability, stability and safety of traditionally insoluble or unstable drugs improving the delivery, efficacy and convenience of treatments for ocular surface diseases including dry eye through preservative free and multi dose formulations. NOVALIQ has developed a tiered and long-term sustainable dry eye family of truly differentiated products that addresses the different needs of dry eye patients. NOVALIQ’s most advanced product is NovaTears® with CE-approval marketed under the brand name EvoTears® in Europe. CyclASol® a second-generation prescription drug is currently in preparation for a pivotal trial. More on www.novaliq.com.
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme tältä julkaisijalta, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
IBC’s Big Screen to Explore the Future of Camera and Display Technologies and the Business Behind Cinema22.8.2017 19:58 | Tiedote
IBC today announced the details of its Big Screen programme, taking place in a specially built auditorium designed to IBC’s specifications and featuring the very latest in cinema technology. With the latest Dolby Vision dramatic imaging and Dolby Atmos immersive audio sound installation, the four-day programme examines and demonstrates the hottest topics, themes, and insights surrounding the art, science, and business of cinema - from capture through to exhibition. As well as being the home of the Big Screen programme, the auditorium will screen in Dolby Vision and Dolby Atmos, Baby Driver, the acclaimed Edgar Wright feature from 2017. The programme for 2017, which has been shaped by a committee of global industry professionals, is an insightful examination of the future of cinema. From virtual reality in cinema to laser and camera assessments, visitors will get up to speed
Digi Communications N.V. Announces the Publishing of an Update to the Investigation by the Romanian National Anti-Corruption Directorate22.8.2017 19:38 | Tiedote
In connection with the investigation triggered by the Romanian National Anti-Corruption Directorate (“DNA”), which we have previously disclosed to the market and to our investors in the initial public offering prospectus dated 26 April 2017, in the supplemental prospectus dated 8 May 2017 (together, the “Prospectus”), as well as in the subsequent public reports, we inform you that, based on the public release no 832/VIII/3 issued on 22 August 2017, the DNA sent to court under the judiciary control Mr. Ioan Bendei (Vice-president of the Board of Directors of RCS & RDS S.A. – the Company’s subsidiary („RCS&RDS”)) in connection with the offences of bribery and accessory to money laundering, as well as RCS&RDS in connection with the offences of bribery and money laundering, INTEGRASOFT S.R.L. (one of RCS&RDS’s subsidiaries in Romania) in connection with the offence of accessory to mon
Meggitt Training Systems to Exhibit at DSEI 201722.8.2017 17:00 | Tiedote
Meggitt Training Systems, the leading provider of integrated live-fire and virtual weapons training products and services for armed forces and law enforcement, will participate at Defence and Security Equipment International (DSEI) through the Georgia Department of Economic Development. The military and security industry event will be held September 12-15, 2017 at ExCeL in London, England. “Today’s threats necessitate maximum realism, despite stretched budgets, and that’s what Meggitt provides to government and commercial customers globally,” said Mark Mears, managing director at Meggitt Training Systems, Ltd. “Although proudly based in Georgia, Meggitt Training Systems is part of Meggitt PLC, a UK-headquartered corporation. As such, we particularly look forward to engaging with current and prospective customers at DSEI, the UK’s largest defense and security trade show.” On
SailPoint Named a Leader in Cloud-based Identity Governance22.8.2017 17:00 | Tiedote
SailPoint, the leader in enterprise identity management, was recently named the overall market leader in KuppingerCole’s 2017 “Leadership Compass: Identity as a Service: Cloud-based Provisioning, Access Governance and Federation.” In addition to being named a leader in every category of the report, SailPoint received superior rankings in four of the five evaluation criteria: security, functionality, interoperability and usability. KuppingerCole is an international and independent analyst organization with a strong focus on Information Security and Identity and Access Management. KuppingerCole’s Leadership Compass reports provide an in-depth analysis of the main players in the market, defining each as a follower, challenger or leader. The Leadership Compass Report for IDaaS evaluates leaders in innovation, product features, and market reach for identity-as-a-service offerings tar
Camelbay Real Estate Management NL B.V. Selects Yardi Voyager22.8.2017 16:58 | Tiedote
Camelbay Real Estate Management NL B.V. will utilise Yardi Voyager® 7S, a browser-agnostic, fully mobile Software-as-a-Service platform, as its accounting and property management platform. Camelbay will use Yardi Voyager to streamline its property management, leasing and accounting processes for its Dutch real estate portfolio, which is predominantly comprised of commercial office assets. “The automation, transparency and fully integrated accounting and property management that Voyager provides will help us manage our daily financial and operational activities more efficiently and enhance our competitive position within the Dutch office market,” said Alon Levy, Director of Camelbay Real Estate Management NL B.V. “We are very pleased to welcome Camelbay as our latest client in the Netherlands,” said Neal Gemassmer, Vice President of International for Yardi.
Laser Design CyberGage®360, Automated 3D Scanning & Inspection System Adopted by Proto Labs in their State-of-the-Art Metrology Lab22.8.2017 16:44 | Tiedote
Laser Design, Inc., a subsidiary of CyberOptics (NASDAQ:CYBE), and premier provider of ultra-precise 3D scanning systems and services, announces the adoption of the CyberGage360 3D Scanning and Inspection system by Proto Labs, the world’s fastest digital manufacturing source for custom prototypes and low-volume production parts providing unprecedented speed-to-market value for designers and engineers. “At Proto Labs, we strive to challenge the traditional rules of manufacturing in order to deliver custom manufactured components at unprecedented speeds,” said Dylan Lundberg, Senior Manufacturing Engineer of Protoworks, Proto Labs’ R&D lab. “Everything we do revolves around reducing our customers’ time to market and we do that by digitalizing the entire manufacturing process. From our front-end services to our proprietary processes on the manufacturing floor, you will find thr
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme